This inventor holds 2 USPTO granted patents. Top assignees: Chengdu Easton Biopharmaceuticals Co., Ltd, Chengdu Easton Biopharmaceuticals Co., Ltd. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Title: The Innovations of Xiaochao Xian
Introduction
Xiaochao Xian is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. His innovative work has led to the development of a new crystal form of lenvatinib mesylate, which has the potential to improve drug formulations for cancer therapy.
Latest Patents
Xian holds a patent for the "Crystal form of lenvatinib mesylate and preparation method therefor." This patent describes a new crystal form of lenvatinib mesylate, a preparation method for this form, and its application in the development of drugs aimed at treating cancer. His work in this area is crucial for advancing cancer treatment options.
Career Highlights
Xiaochao Xian is associated with Chengdu Easton Biopharmaceuticals Co., Ltd., where he continues to innovate in the pharmaceutical sector. His dedication to research and development has positioned him as a key figure in the industry. With a focus on improving drug efficacy, Xian's contributions are paving the way for better therapeutic solutions.
Collaborations
Xian collaborates with talented professionals in his field, including Ying Wang and Xuehai Pang. These partnerships enhance the research and development efforts at Chengdu Easton Biopharmaceuticals Co., Ltd. Together, they work towards advancing pharmaceutical innovations.
Conclusion
Xiaochao Xian's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in cancer treatment, highlight the importance of research and development in creating effective therapies. His ongoing efforts will undoubtedly continue to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile